Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare CED Could Enhance Efficiency Of FDA Post-Approval Studies – CMS Draft Guidance

Executive Summary

Medicare’s coverage with evidence development policy could help enhance the efficiency of research conducted under FDA post-approval requirements, CMS says in a draft guidance on CED released Nov. 29.

Advertisement

Related Content

Medicare To Use Evidence Development For Off-Label Drug Use? CMS Guidance Unclear
Cohesive Coverage-With-Evidence Authority Needed For Medicare, Lawmakers Told
Medicare CED Could Enable Expanded Use Of Expedited Drug Approvals, Policy Groups Suggest

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054938

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel